Junshi biological terminates its cooperation with AstraZeneca

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

XR Service Company GHZ-Tech Nets more than 10 Mn in Angel Round

The strongest demand for XR industrial applications at this stage is in the fields of cultural tourism exhibition and education, while the demand in the industrial field is increasing because certain scenes or processes in the industrial field can also be standardized.

hibobi: Unlocking Global Success with Localization Strategy in Diverse Markets

The market in the Middle East has recently gained considerable attention from entrepreneurs worldwide. The hibobi Group, a pioneer in this emerging market, has unique insights in branding and supply chain construction.

Chip Design Company CMind Completes Pre-A+ Round Financing, 5G Chip Tape out in Q3

Domestic mobile communication chip market is huge, 5G IOT and telematics market is still in the blue ocean, and the market compound annual growth rate is at the forefront of the semiconductor industry.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.